Just after four cycles of neoadjuvant use, the combination of Roche’s pertuzumab, Herceptin (trastuzumab) and chemotherapy improved the rate of complete tumor disappearance by more than half compared to conventional therapy in patients with HER2-positive breast cancer.
The results came from the NEOSPHERE study which randomized 417 women with newly diagnosed HER2-positive early-stage breast cancer to one of four treatment arms prior to surgery.
The results showed that nearly half of the women (45.8 percent) who received pertuzumab plus Herceptin, in combination with chemotherapy had complete tumor disappearance at the time of surgery compared with 29 percent of those who received Herceptin in combination with chemotherapy.
Most importantly, the combination of pertuzumab and Herceptin with chemotherapy did not lead to a significant increase in cardiac side-effects when compared to Herceptin plus chemotherapy.
Please visit healthreason.com for more health related articles.
